To identify prognostic factors for overall survival after recurrence (OSr) in endometrioid endometrial cancer (EC) patients and categorize patient subgroups that predict outcomes using these variables.
Introduction
An estimated 319,600 new cases of endometrial cancer (EC) occurred worldwide in 2012. [1] In developed countries, EC is the most commonly diagnosed gynecologic cancer with over 167,000 new cases in 2012. [1] The EC incidence rate has been increasing in Korea, where more than 1700 cases are diagnosed annually. [2] Although most EC patients are diagnosed with early-stage disease and have a favorable prognosis, approximately 15% of these patients relapse. [3] Treatment for recurrence includes local treatment (radiotherapy or surgery), systemic chemotherapy, or relevant combinations. It differs according to the involved site, recurrent disease extent, and types of previous therapy. [4] The 3-year survival rate in recurrent EC patients is reported to be between 8% and 73%. [5] This broad range indicates that recurrent EC patients represent a heterogeneous group with different prognostic factors for survival. Thus, there is a need to better discriminate these patients depending on prognosis after relapse. Although a handful of studies have suggested several prognostic factors associated with survival after recurrence, [6] [7] [8] [9] [10] [11] the individualized prediction model incorporating these risk factors has not been introduced.
Therefore, the present study aimed to develop a prediction model incorporating the prognostic factors for survival after recurrence in endometrioid EC patients and stratify the patients into subgroups according to survival outcomes.
Materials and methods

Patients
With approval from the institutional review board (S2015-1754-0001), records were retrieved retrospectively from a computerized database of patients diagnosed with primary EC in our institution between 1989 and 2013. Patients who received primary surgery (at least hysterectomy and/or bilateral salpingooophorectomy) for endometrioid EC were considered eligible for the study. Patients with non-endometrioid histologies (such as malignant mixed Müllerian tumors, papillary serous, clear cell, and undifferentiated carcinomas) were excluded from this study. Patients who received fertility-sparing treatment, lacked followup information, did not have a disease-free interval of at least 3 months, had concomitant ovarian or fallopian tube carcinoma, and/or had a history of another malignancy or underlying disease potentially affecting survival were also excluded. Recurrence was defined as the occurrence of disease after a disease-free interval of 3 months or more. [12] The initial surgical procedures for EC used in our institution have been described previously. [13] In cases with deep myometrial invasion (≥50%), tumor size >2 cm in diameter, International Federation of Gynecology and Obstetrics (FIGO) stage II to IV, and grade 2 to 3, a comprehensive surgical staging procedure (including pelvic and/or para-aortic lymphadenectomy) was performed. All histologic specimens were microscopically evaluated by gynecologic pathologists for myometrial invasion, grade, histology, cervical invasion, and nodal metastasis. Adjuvant treatment was individualized depending on histology, stage, grade, and the discretion of the physician. [4] After completion of the primary treatment, patients were evaluated by a gynecologic oncologist every 3 months for the first 2 years, every 6 months for the subsequent 3 years, and annually thereafter. Each follow-up visit included history-taking, physical examination, serum cancer antigen-125 (CA-125) measurements, and vaginal cytology. When recurrence was suspected clinically, it was confirmed using histopathological examination or radiological examinations, such as computed tomography. Local recurrence was defined as that confined to the vagina, regional recurrence was defined as disease limited to the false pelvis, and distant recurrence was defined as disease beyond the false pelvis. [11] Treatment modalities for recurrence were selected with consideration of the site of recurrence, and number and type of previous treatments. Radiotherapy was selected for local vaginal or regional lymph node recurrences. Salvage surgery was considered for patients with resectable isolated or a limited number of recurrent lesions. In cases where recurrence was not amenable to local treatment such as surgery or radiotherapy, chemotherapy was selected.
Variables and statistical analysis
The following clinicopathological variables were extracted from electronic medical records: age, body mass index (BMI), parity, menopause, primary surgical procedure, initial FIGO stage, initial pathological findings (including histology, grade, myometrial invasion, lymph node metastasis), information regarding adjuvant therapy, age at the time of recurrence, symptomatic recurrence, [10] time to relapse (TTR; from the completion date of initial treatment to the date of recurrence detected), location of recurrence, number of recurrent lesions, CA-125 level at the time of recurrence, and treatment modalities for recurrence. If the patient received multiple treatments for recurrence, the treatment of the first detected recurrence was evaluated. Initial surgical stage of patients with recurrence was determined using the 2009 FIGO staging system. [14] Of the variables that were tested, age at initial diagnosis, BMI, age at the time of recurrence, and CA-125 level at the time of recurrence were considered as continuous variables. Initial stage, grade (1, 2, and 3), location (local, regional, and distant), and number (single and multiple) of recurrent lesions, TTR (<6 and ≥6 months), symptomatic recurrence, and treatment type for recurrence (surgery, radiation, and chemotherapy) were considered as categorical variables. We chose 6 months as the cut-off value to test whether this variable is a prognostic factor for survival after recurrence given the results of previous studies. [8, 15] A CA-125 level of ≥35 U/mL was considered to be elevated. [16] The primary end point was overall survival after recurrence (OSr), which was calculated from the date of confirmed recurrence to the date of death, or the date of the last followup for surviving patients. Patients were censored if they were alive at last contact or died without disease. For 12 recurrent EC patients who were lost to regular follow-up, it was possible to obtain definitive survival data from the National Cancer Information Center database. Thus, definitive survival data were available for every recurrent endometrioid EC patient. Survival curves were plotted with the Kaplan-Meier method and compared using the log-rank test. A multivariate Cox regression mode was used to identify the independent prognostic factors for OSr. All significant variables after univariate analysis were entered into a multivariate Cox regression model, and nonsignificant variables were removed in a stepwise fashion. The risk of cancer-specific death was calculated using adjusted hazard ratios (HRs) from this multivariate model. The prognostic score generated for each significant factor was proportionate to the HR. Patients were categorized into 3 subgroups based on the sum of the scores. A P value < .05 according to 2-sided tests indicated significant difference. All analyses were performed using SPSS version 19.0 (SPSS, Chicago, IL).
Results
Patients
During the study period, 1302 patients with EC underwent primary surgery. Of these patients, 108 developed recurrence and were analyzed ( Supplementary Fig. 1 , http://links.lww.com/MD/ B702). The characteristics of the patients with recurrence are summarized in Table 1 . The median age at initial treatment and recurrence was 54 years (range, 24-79 years) and 56 years (range, 27-80 years), respectively. At initial diagnosis, 41 patients (38%) had FIGO stage I/II disease. For the initial surgical procedure, 93 patients underwent pelvic lymphadenectomy and 62 underwent para-aortic lymphadenectomy. Pelvic and para-aortic nodal metastases were found in 45 and 35 patients by pathological evaluation, respectively. Ninety-one patients (84%) received adjuvant therapy after primary surgery: 40 (37.0%) had chemotherapy (37 received a platinum-based combination regimen and 3 received paclitaxel only), 26 (24.1%) had radiotherapy, and 25 (23.1%) had a combination of both. Thirty-seven patients (34.3%) showed symptoms of recurrence. The main symptoms at recurrence were vaginal bleeding (n = 14), abdominal pain (n = 13), and respiratory symptoms (n = 8).
Treatment for relapse
The treatments given for recurrence are described in Table 2 . Locoregional and distant recurrences were diagnosed in 20 and 88 patients, respectively. One hundred three patients underwent salvage therapy including radiotherapy, surgery, chemotherapy, or combined therapy. The other 5 patients received palliative treatment alone because their poor performance status contra-
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Medicine indicated salvage therapy. Forty-four (41%) received combined therapy. Those with distant recurrence tended to receive chemotherapy only (45/88; 51%), whereas those with locoregional recurrence were more likely to receive radiotherapy or surgery (14/20; 70%). Twenty-nine patients (27%) with solitary or a limited number of recurrent lesions underwent salvage surgery, and the specific sites of recurrence were as follows: lung (n = 9), pelvic (n = 6), retroperitoneal lymph node (n = 5), vagina (n = 4), intra-abdominal (n = 3), and brain (n = 2).
Univariate and multivariate analyses of prognostic factors for OSr
The median follow-up period for the 108 patients was 45 months (range, 4-301 months Univariate Cox regression analysis revealed that TTR (P < .001), CA-125 level at recurrence (P < .001), number of recurrent lesions (P = .003), and initial stage (P = .007) were associated with OSr. After performing multivariate analysis to control for these variables, TTR, CA-125 level at recurrence, and number of recurrent lesions remained as significant prognostic factors (Table 3) .
Stratification of subgroups to predict OSr
Using 3 independent prognostic variables for OSr, we generated a scoring system and stratified 3 subgroups according to the scores. For TTR, we assigned a score of 0 for ≥6 months and 1 for <6 months. For number of recurrent lesions, we assigned a score of 0 for single and 1 for multiple. For CA-125 level at recurrence, we assigned a score of 0 for 35 U/mL and 1 for >35 U/mL (Table 3) .
According to the sum of scores, we stratified patients into 3 risk groups; the low-risk group (n = 19) was defined as patients with a score of 0. The intermediate-risk group (n = 43) was defined as patients with a score of 1. The high-risk group (n = 46) was defined as patients with a score of 2 or 3. Figure 1 shows the OSr in the low-, intermediate-, and high-risk groups. The 3-year OSr rates in each group were 81%, 54%, and 14%, respectively, and the 5-year OSr rates in each group were 71%, 42%, and 9%, respectively. The OSr differed significantly among the risk groups BMI = body mass index, BSO = bilateral salpingo-oophorectomy, CA-125 = cancer antigen-125, FIGO = International Federation of Gynecology and Obstetrics, PALND = para-aortic lymph node dissection, PLND = pelvic lymph node dissection. Table 2 Numbers of patients who received a spectrum of treatments after recurrence stratified by site of recurrence.
Site of recurrence Local (n = 7) Regional (n = 13) Distant (n = 88) 
Discussion
Recurrent EC is a highly heterogeneous entity, with a broad spectrum of survival outcomes. [4] Although the prognosis for the vast majority is poor, a specific group shows long-term survival after recurrence. In the present study, TTR, CA-125 level at recurrence, and number of recurrent lesions were revealed as significant factors for OSr in recurrent endometrioid EC patients. When we stratified patients into 3 subgroups by combining weighted prognostic factors, the OSr differed significantly among the risk groups. Our risk stratification model was designed as a user-friendly and simple scoring system. Meanwhile, the traditional multivariate regression model suggests a mathematically complicated formula, which is difficult for both clinicians and patients to apply and interpret in clinical practice. Considering the heterogeneous characteristics of the recurrent EC population, our model would be clinically useful for predicting outcomes, counseling patients, and designing future clinical trials.
Previous studies reported that 70% to 86% of incidences of recurrence are detected within 3 years after primary treatment and that the 3-year OSr is 17% to 35%, [6, 10, 17] findings similar to our results. However, only a handful of studies addressed the prognostic factors associated with OSr in these patients and as yet there is no consensus. Table 5 summarizes the published studies reporting the prognostic factors for OSr in recurrent EC patients. Commonly suggested prognostic factors for OSr include TTR, [6, 8, [15] [16] [17] [18] [19] [20] [21] [22] number of recurrent lesions, [21, 23, 24] site of recurrence, [5, 6, 9, 16, 22, 25, 26] CA-125 level at recurrence, [24, 27] histology, [20] grade, [9, 10, 28] initial stage, [10] symptomatic recurrence, [10, 17, 18, 29] performance status, [8] and use of pelvic radiation after initial surgery. [5, 6, 8, 22, 23] To build a reliable model, we tested all aforementioned variables for inclusion.
In the present study, multiple recurrent lesions were independent poor prognostic factors for OSr. A retrospective study by Sohaib et al [23] of 86 recurrent EC cases suggested that multiple recurrent lesions were independent prognostic factors. Similarly, Table 3 Univariate and multivariate Cox regression analyses of the prognostic factors associated with overall survival after recurrence. 
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Odagiri et al [21] reported that the number of recurrent lesions was an independent prognostic factor for OSr in 35 recurrent EC patients. In 2015, Turan et al [24] reported that multiplicity of recurrent lesions was associated with poor survival rates among 34 recurrent EC patients undergoing salvage cytoreductive surgery. One possible reason for this finding is that multiple recurrent lesions are indicative of the metastatic potential of EC cells and reflect inherent tumor aggressiveness. [5, 21] Another possible explanation is that salvage surgery is generally performed in select cases with a single or limited number of recurrent lesions. In an analysis of 64 patients undergoing surgery for recurrent EC by Papadia et al, [30] multiplicity of the recurrent lesions was significantly associated with incomplete resection. Moreover, a meta-analysis indicated that, if complete cytoreduction of recurrent tumors is achieved, survival is improved in recurrent EC patients, regardless of the disease location. [31] In the present study, 16 patients with an isolated recurrent lesion underwent salvage surgery and none of them had any gross residual disease after salvage surgery. Of those patients, 8 had prolonged survival (>3 years).
In addition to the number of recurrent lesions, TTR also affected OSr in multivariate analysis, which is consistent with previous studies. [6, 8, [15] [16] [17] [18] [19] [20] [21] [22] Although this variable may be indicative of a general prognostic factor in terms of tumor biology, it is still conflicting that this reflects tumor response to a second-line platinum-based chemotherapy, which means the concept of "platinum sensitivity" a term historically reserved for ovarian cancer. A retrospective study by Ueda et al [15] reported that patients with a TTR of >6 months had better response rates to salvage chemotherapy compared to those with a TTR of <6 months. Similarly, a multicenter retrospective study of 262 recurrent EC patients by Nagao et al showed that a platinum-free interval is a predictor of tumor response and survival after second-line platinum-based chemotherapy. [19] By contrast, such a time interval was not associated with tumor response to secondline chemotherapy in an ancillary analysis using pooled data from 5 phase III Gynecologic Oncology Group trials. [8] Interestingly, a time interval from primary treatment to recurrence of >6 months was still prognostic for survival after second-line chemotherapy in this analysis (HR = 0.70, 95% CI = 0.59-0.84, P < .05). Future studies are warranted to elucidate whether this variable has clinical utility in selection of the chemotherapy regimen for recurrent EC as is the case for ovarian cancer.
Assay of serum CA-125 may be useful for surveillance in EC patients after initial treatment, if levels were initially elevated. [32] Routine use of serum CA-125 varies across institutions, and furthermore the benefit of surveillance to detect asymptomatic disease is controversial. In our institution, serum CA-125 Figure 1 . Overall survival after recurrence by the sum of prognostic scores (A) and risk groups (B). Patients with a total prognostic score of 0 were categorized as the low-risk group (n = 19), patients with a prognostic score of 1 were categorized as the intermediate-risk group (n = 43), and patients with a prognostic score of 2 or 3 were categorized as the high-risk group (n = 46). Table 4 Stratification of subgroups predicting overall survival after recurrence in patients with recurrent endometrioid endometrial cancer by the combination of independent prognostic factors.
Risk group
No. of patients Sum of scores * HR (95% CI) P CA-125 = cancer antigen-125, CI = confidence interval, HR = hazard ratio. * Sums of risk factors including time to relapse (<6 mo), number of recurrent lesions (2 or more), and CA-125 level at recurrence (>35 U/mL). The presence of each risk factor above the cut-off, according to the Cox regression analysis, is represented by a score of 1.
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www.md-journal.com Table 5 Published studies reporting the prognostic factors for survival after recurrence in recurrent endometrial cancer patients. measurement is used for post-treatment surveillance in EC patients. In the present study, the CA-125 level at recurrence for all enrolled patients was available, and was revealed as a significant prognostic factor for OSr. In 2015, Turan et al [24] reported that CA-125 level at recurrence was prognostic in recurrent EC patients undergoing salvage cytoreductive surgery.
In their series of 34 cases, the mean overall survival was 22 and 58 months in patients with levels of CA-125 at recurrence >27 and <27 IU/mL, respectively (P < .05). Elevated serum CA-125 levels at initial diagnosis correlated with extrauterine tumor extension and lymph node metastases. [33, 34] Similarly, elevated serum CA-125 level at recurrence closely correlates with the peritoneal dissemination of cancer cells and an increased metastatic potential. [33] Site of recurrence is a well-known prognostic factor for recurrent EC [5, 6, 9, 16, 22, 25, 26] ; however, this was not observed in the present study. This may be due to the small number of cases with isolated vaginal recurrence (n = 7). The incidence of vaginal recurrence can be altered by administration of adjuvant radiation. In the Post Operative Radiation Therapy in Endometrial Cancer-1 (PORTEC-1) trial, isolated vaginal recurrence occurred in 2% of patients who received adjuvant radiotherapy, whereas it occurred in 8% of those who did not. [35] Another possible explanation is that the majority (5/7; 71%) of patients with local recurrence had received adjuvant radiotherapy previously. Although radiotherapy is the treatment of choice for radiotherapy-naive patients with vaginal recurrence, treatment for vaginal recurrence within a previously irradiated field may include surgery or additional radiotherapy. [36] However, if surgery or radiotherapy is not possible, the prognosis is worse since the treatment of choice becomes similar to that used for metastatic disease such as hormonal or cytotoxic agents. [37] As demonstrated in the PORTEC-1 trial, the 3-year OSr rate in patients with vaginal recurrence who received adjuvant radiotherapy was lower (43%) than that (65%) in radiotherapy-naive patients. [5] Regarding the grade, published studies have shown conflicting results of whether this variable is a prognostic factor for survival after recurrence. As summarized in Table 5 , 3 retrospective reviews showed that the grade is a prognostic indicator of survival after recurrence. [9, 10, 28] Of these reviews, the study by Berchuck et al was conducted at a time when the guidelines for postoperative radiation therapy for high-and intermediate-risk patients were not standardized. [9] In a study by Esselen et al, the controlling variables for multivariate analysis only included age, stage, and myometrial invasion. [28] They did not include CA-125 level, TTR, or number of recurrent lesions. These features may explain why our result is not consistent with those of other studies.
With advances in treatment modalities such as surgery and chemotherapy, [31, 38] long-term survival of recurrent EC patients has improved. In the 1960 to 1976 cohort study by Aalders et al, the 5-year OSr rate for recurrent EC was 13%. [12] Radiotherapy was the most commonly used treatment for recurrence (64%), followed by hormone therapy (29%). However, in the 1990 to 2006 cohort study by Smith et al, recurrent EC patients had a 5-year OSr rate of 32%. [10] Salvage surgery and chemotherapy were more often prescribed for the 1990 to 2006 cohort. In the current study, the 5-year OSr rate of the 108 cases was 30%, which seems remarkably good considering the high proportion (82%) with distant recurrence. Nonetheless, the majority of recurrent EC cases still carry a poor prognosis. In cases of recurrence that develop after initial multimodal adjuvant treatment, salvage therapy can be challenging. Recently, data from the Cancer Genome Atlas suggest that in EC there are 4 genomic subtypes with different biology and prognosis, which presents the possibility of revealing druggable molecular aberrations. [39] To date, some molecular-targeted agents, such as anti-angiogenic therapies and poly ADP ribose polymerase inhibitors, and immunotherapies, appear to have clinical activity in the recurrent setting. [40, 41] Our study has several limitations inherent to its retrospective nature. First, the selection of patients for salvage treatment depended on previous adjuvant treatment, performance status, and the physician preferences. Second, the results of our study will require corroboration from other independent data sets to be applicable to the general population. It would be better if the scoring system could be validated using independent data from other sources. Further studies focusing on external validation by other institutions are needed. Third, this study covered a 20-year period, during which the adjuvant treatment for EC changed. The advancements in cancer care and treatment during this long period may have improved the survival rate. Therefore, such a long study period could potentially cause selection bias. Nonetheless, the number of enrolled patients was large compared with previous studies. Moreover, in the public healthcare system of Korea, which covers almost all the Korean population, it is mandatory to register the death with cause for cancer patients into the National Cancer Information Center database; definitive survival data were therefore available for all enrolled patients, including 12 (11%) who were lost to regular follow-up at our institution.
In conclusion, we found that TTR, CA-125 level at recurrence, and number of recurrent lesions were significant factors for OSr in recurrent endometrioid EC patients. When we stratified the patients into 3 subgroups considering these factors, their OSr differed among groups. After external validation, this model could be valuable in terms of predicting outcomes and planning clinical trials. Although individualized multimodal salvage therapy has led to an improvement in survival for a specific group, further efforts are necessary to facilitate new treatment strategies, such as moleculartargeted agents, for recurrent EC patients who still have poor prognosis.
